Parent patent

The ZambonU.S. Patent18 covered processes only. Product claims to intermediates were divided out from that parent patent, in both the United States and Europe, and became the subject of a later patent.19... 

A patent family includes the parent patent which has the priority and the relevant foreign and corresponding applications. 

Figure 12 shows that the Japanese patent has the priority but the patent publication had not arrived at Chemical Abstracts Service at the time the abstract was written about the European patent. The situation is particularly difficult with American patents because under US patent law there is only one step after application Only when the patent is granted is the document published (see example in Sect. 2.6). That means, if a US patent document is cited everybody knows that the patent has been granted. In all other patent processes the patent document will be published as an application and later once again when it is granted. With a European patent application the priority has to be named -this gives, in the case of a patent family, the cross-reference to the parent patent - and will be cited in the corresponding CA abstracts. 

For this Japanese patent the patent family is listed starting with additional Japanese patents which belong to the parent patent and claim its priority, too (indicated through the addition related). It is not possible to identify the parent patent from this listing because CAS abstracts the first patent which arrives at CAS which is not necessarily the parent patent. These additional patents have their own abstracts if they include several details or pieces of information which are not contained in the parent Japanese patent. The related US patent also received its own abstract, so the whole patent family is described by three CA abstracts. 

The Patent Index refers from the questioned US patent 5,158,840 to a European patent (Fig. 47). The A after the American patent number indicates that the patent has been granted, the A1 after the EP number shows that at this time Chemical Abstracts Service has become aware of this patent as a patent application. The patent family is shown under the number of the European patent (Fig. 48) Firstly the codes for those countries are named for which the protection by the European patent is registered - in this case there are four countries Germany, France, the United Kingdom and Sweden. This is followed by the respective CA abstract number. It also states that a Japanese patent belonging to this family has been submitted. In the listing of a patent family it is not possible to identify which is the parent patent holding the priority. 

Basic patent the patent document in a database, which the database producer receives as the first one of a patent family and all additional applications are linked with It is not necessarily the parent patent, which holds the —> priority ... 

Corresponding application patents which are applied in different countries but have a link to the parent patent, are members of a patent family. 

Parent patent -> basic patent, patent family... 

Patent family consists of the parent patent, which holds the -> priority (in contrast to the basic patent), and the related and -> corresponding applications filed abroad. 

As 1,2,5-thiadiazole analogues, potent HlV-1 reverse transcriptase inhibitors, some simple 1,2,5-oxadiazoles, compounds 4-6 (Fig. 9), have been synthesized using the traditional Wieland procedure as key for the heterocycle formation [121]. Such as thiadiazole parent compounds, derivative with chlorine atoms on the phenyl ring, i.e., 5, showed the best anti-viral activity. Selectivity index (ratio of cytotoxic concentration to effective concentration) ranked in the order of 5 > 6 > 4. The activity of Fz derivative 6 proved the N-oxide lack of relevance in the studied bioactivity. These products have been claimed in an invention patent [122]. On the other hand, compound 7 (Fig. 9) was evaluated for its nitric oxide (NO)-releasing property (see below) as modulator of the catalytic activity of HlV-1 reverse transcriptase. It was found that NO inhibited dose-dependently the enzyme activity, which is hkely due to oxidation of Cys residues [123]. 

All other approaches try and relate the child spectra to the parent spectra. In the patented method of Shenk and Westerhaus [41 Sh], in its simplest form, one first applies a wavelength correction and then a correction for the absorbance. Each wavelength channel i of the parent instrument is linked to a nearby wavelength channel j(i) in the child instrument, namely the one to which it is maximally correlated. Then, for each pair of wavelengths, i for the parent and j i) for the child, a simple linear regression is carried out, linking the pair of measured absorbances... 

A close analogue of (385), the 4-hydroxypiperidine analogue (386) was recently described in a patent application from Sanofi-Synthelabo [271] and perhaps formed as a metabolite of the parent compound. 

Very little is known about the parent benzoxazine analogue,1 due to difficulties in the preparation of o-nitrosophenol. Synthetic procedures and practical application of spironaphthooxazines can be found in the patent literature and have been reviewed.72... 

A BDS patent [106] was awarded for the use of biocatalysts belonging to the group of Pseudomonas, Flavobacterium, Enterobacter, Aeromonas, Bacillus, or Corynebac-terium. One of the strains P. putida was further developed by mutation of the parent strain to obtain organic solvent-resistant mutants [107], The mutated strains were screened by selective cultivation in the presence of 0.1% to 10% by volume (v/v) of concentrations of a toxic organic solvent. The specific mutated strains obtained were P. putida No. 69-1 (PERM BP-4519), P. putida No. 69-2 (PERM BP-4520), and P. putida No. 69-3 (PERM BP-4521). 

Gorner, P., "Parents Suing Over Patenting of Genetic Tests They Say the Researchers They Assisted Are Trying to Profit from a Test for a Rare Disease," Chicago Tribune, p. Cl (Nov. 19, 2000). 

Energy Conversion Devices (ECD) of Troy, Michigan has announced a potential breakthrough in solid hydrogen storage. ECD is one of the parent companies of GM Ovonics, patent holder for the nickel metal hydride battery. A hydride, by definition, is a solid material that stores hydrogen. 

When the first Moss Bill was filed, its provisions were studied by the American Chemical Society Committee on Economic Status and the Committee on Patent Matters and Related Legislation. One concern was whether an official ACS position on the bill should be presented to the governing congressional committee. The ACS bodies also felt that consideration should be given to the active involvement of ACS itself in developing a program for encouraging compensation to employed inventors. It soon became apparent to the members of the two ACS Committees that the issue was more complex than appeared, and a joint subcommittee was appointed to study the entire question in depth. This subcommittee, under my chairmanship, has been active since 1972, and it made a report to its parent committees in the fall of 1974 with recommendations for future action. 

---